7595-60-0

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
METHYL 1-(4-NITROPHENYL)-4-PIPERIDINECARBOXYLATE is used as a key intermediate in the synthesis of potential drug candidates, contributing to the discovery of new therapeutic agents.
Used in Medicinal Chemistry:
As a piperidine derivative, METHYL 1-(4-NITROPHENYL)-4-PIPERIDINECARBOXYLATE is used as a structural component in the design and modification of novel compounds with potential medicinal applications.
Used in Pharmacological Studies:
METHYL 1-(4-NITROPHENYL)-4-PIPERIDINECARBOXYLATE is employed as a test compound in pharmacological studies to investigate its potential analgesic effects and its ability to modulate the activity of certain neurotransmitters, which could lead to the development of new treatments for pain management and neurological disorders.
Used in Chemical Synthesis:
In the chemical synthesis industry, METHYL 1-(4-NITROPHENYL)-4-PIPERIDINECARBOXYLATE is used as a reactant or building block for the creation of more complex organic molecules with specific applications in various fields, including materials science and specialty chemicals.

InChI:InChI=1/C13H16N2O4/c1-19-13(16)10-6-8-14(9-7-10)11-2-4-12(5-3-11)15(17)18/h2-5,10H,6-9H2,1H3

Upstream product

• 2971-79-1 isonipecotic acid methyl ester 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 471938-27-9 methyl 1-(4-aminophenyl)piperidine-4-carboxylate 
• 1445868-97-2 5-[1-(4-[(E)-1-(5-nitro-2-furyl)methylidene]aminophenyl)-4-piperidyl]-2,3-dihydro-1,3,4-oxadiazol-2-one 
• 1445868-98-3 3-methyl-5-[1-(4-[(E)-1-(5-nitro-2-furyl)methylidene]aminophenyl)-4-piperidyl]-2,3-dihydro-1,3,4-oxadiazol-2-one 
• 1445868-99-4 3-ethyl-5-[1-(4-[(E)-1-(5-nitro-2-furyl)methylidene]aminophenyl)-4-piperidyl]-2,3-dihydro-1,3,4-oxadiazol-2-one 
• 1445869-00-0 3-benzyl-5-[1-(4-[(E)-1-(5-nitro-2-furyl)methylidene]aminophenyl)-4-piperidyl]-2,3-dihydro-1,3,4-oxadiazol-2-one 
• 1445869-05-5 5-[1-(4-[(5-nitro-2-furyl)methyl]aminophenyl)-4-piperidyl]-2,3-dihydro-1,3,4-oxadiazol-2-one 
• 1445869-06-6 3-methyl-5-[1-(4-[(5-nitro-2-furyl)methyl]aminophenyl)-4-piperidyl]-2,3-dihydro-1,3,4-oxadiazol-2-one 
• 1445868-89-2 N-4-[4-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)piperidino]phenyl-5-nitro-2-furamide 
• 1445869-07-7 3-ethyl-5-[1-(4-[(5-nitro-2-furyl)methyl]aminophenyl)-4-piperidyl]-2,3-dihydro-1,3,4-oxadiazol-2-one 
• 1445869-08-8 3-benzyl-5-[1-(4-[(5-nitro-2-furyl)methyl]aminophenyl)-4-piperidyl]-2,3-dihydro-1,3,4-oxadiazol-2-one 
• 1445868-90-5 N-4-[4-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)piperidino]phenyl-5-nitro-2-furamide 
• 1445869-21-5 1-(4-nitrophenyl)-4-piperidinecarbohydrazide 
• 1445869-22-6 5-[1-(4-nitrophenyl)-4-piperidyl]-2,3-dihydro-1,3,4-oxadiazol-2-one 
• 1445869-24-8 3-methyl-5-[1-(4-nitrophenyl)-4-piperidyl]-2,3-dihydro-1,3,4-oxadiazol-2-one 

Relevant academic research and scientific papers

Porphyrin Donor and Tunable Push–Pull Acceptor Conjugates—Experimental Investigation of Marcus Theory

We report on a series of electron donor–acceptor conjugates incorporating a ZnII–porphyrin-based electron donor and a variety of non-conjugated rigid linkers connecting to push–pull chromophores as electron acceptors. The electron acceptors comprize multicyanobutadienes or extended tetracyanoquinodimethane analogues with first reduction potentials ranging from ?1.67 to ?0.23 V vs. Fc+/Fc in CH2Cl2, which are accessible through a final-step cycloaddition–retroelectrocyclization (CA-RE) reaction. Characterization of the conjugates includes electrochemistry, spectroelectrochemistry, DFT calculations, and photophysical measurements in a range of solvents. The collected data allows for the construction of multiple Marcus curves that consider electron-acceptor strength, linker length, and solvent, with data points extending well into the inverted region. The enhancement of electron–vibration couplings, resulting from the rigid spacers and, in particular, multicyano-groups in the conformationally highly fixed push–pull acceptor chromophores affects the charge-recombination kinetics in the inverted region drastically.

HETEROCYCLIC COMPOUND

The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Nitrofurfuryl Substituted Phenyl Linked Piperidino-Oxadiazoline Conjugates As Anti-Tubercular Agents And Process For The Preparation Thereof

The present invention provides nitrofurfuryl substituted phenyl linked piperidino-oxadiazolone compounds of general formula (A) as anti-tubercular agents; wherein G=formula (B); X═H, F; R═H, CH3, C2H5, Benzyl.

SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS

Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, R4 and m are as defined in the specification.

NITROFURFURYL SUBSTITUTED PHENYL LINKED PIPERIDINO-OXADIAZOLINE CONJUGATES AS ANTI-TUBERCULAR AGENTS AND PROCESS FOR THE PREPARATION THEREOF

The present invention provides nitrofurfuryl substituted phenyl linked piperidino-oxadiazolone compounds of general formula (A) as anti-tubercular agents; wherein G= formula (B); X=H, F; R=H, CH3, C2H5, Benzyl.

DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS

Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.